TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today follow-on positive in-vivo results for CGEN-856 and CGEN-857, two novel peptide agonists of the MAS G-protein coupled receptor (GPCR), the discovery of which was disclosed by the Company last year. These results, obtained from a series of recently completed studies, demonstrate both the cardioprotective and anti-hypertensive effects of these two product candidates.
